Regeneron Wins Antitrust Case Against Amgen, Safeguarding Biotech Innovation and Patient Access to Life-Saving PCSK9 Therapies

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a significant legal victory after a jury in the U.S. District Court for the District of Delaware ruled that Amgen Inc. violated multiple antitrust and tort laws. The jury found that Amgen unlawfully leveraged…










